Drugs / Feladilimab
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03447314 | Mar 2018 → Jul 2020 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT02723955 | Jun 2016 → Jul 2023 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07217119 | Nov 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04126200 | Oct 2019 → Apr 2025 overdue | plasma cell myeloma | GlaxoSmithKline | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03693612 | Nov 2018 → Jun 2021 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06790303 | Mar → Sep 2021 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 2 | NCT03739710 | Jan 2019 → May 2024 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT05553808 | Jan 2019 → Sep 2021 | neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT04428333 | Aug 2020 → Apr 2021 | head and neck neoplasm | GlaxoSmithKline | Terminated | Missed primary |
| Phase 3 | NCT04128696 | Nov 2019 → Apr 2021 | head and neck carcinoma | GlaxoSmithKline | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-09-28 | GlaxoSmithKline | Results GSK presents new data showing promising anti-tumour activity with GSK3359609, an ICOS receptor agonist, in combination with pembrolizumab in head and neck squamous cell carcinoma (HNSCC) gsk.com ↗
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody designed to selectively enhance T cell function, showed promising anti-tumour activity in combination with pembrolizumab in PD-1/L1 naive patients with head and neck squamous cell carcinoma (HNSCC). |
All press releases naming this drug 2 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Feladilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04126200 ↗ |
| Known as | 3359609 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297969 ↗ |
| Known as | GSK-609 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297969 ↗ |
| Known as | GSK3359609 | “feladilimab (GSK3359609) administered continuously” NCT02723955 ↗ |
| Action | Activate | “Stimulation of the T-cell activation marker ICOS with the anti-ICOS agonist mAb feladilimab” PMID 37593752 ↗ Aug 2023 |
| Modality | Monoclonal antibody | “Using a novel clinical-stage anti-ICOS immunoglobulin G4 mAb (feladilimab)” PMID 37593752 ↗ Aug 2023 |
| Route | Intravenous | “GSK3359609 80 mg administered at Q3W via the IV route” NCT03447314 ↗ |
| Target | ICOS | “anti-ICOS immunoglobulin G4 mAb” PMID 37593752 ↗ Aug 2023 |